BCL2 and non-small cell lung carcinoma: Fujita et al. confirmed that an miR-197 was down-regulated in platinum-resistant NSCLC samples, leading to activation of various oncogenes (Bcl-2, C-myc and Cyclin D1), promoting chemotherapy resistance, tumorigenicity and lung metastasis (Fujita et al., 2015).